Pediatric Glioblastoma: What Makes It Different from Adult GBM

If a child in your family has just been diagnosed with pediatric glioblastoma or a pediatric high-grade glioma, the first thing to understand is this: these tumors are not smaller versions of adult GBM. They are biologically different diseases with different molecular drivers, different chemotherapy responses, and different treatment considerations. That distinction matters enormously when you are trying to evaluate whether the plan in front of you is the right one for your child.

This article explains the key differences between pediatric and adult glioblastoma, what survival data shows by age and subtype, how treatment differs for children, and how caregivers can get expert review, including from specialist centers outside your local area.

What Is Pediatric Glioblastoma?

Pediatric glioblastoma is a grade 4 malignant brain tumor occurring in children and adolescents. It belongs to a broader category called pediatric high-grade gliomas (pHGG). In 2021, the World Health Organization updated its classification of central nervous system tumors and formally separated pediatric-type high-grade gliomas from adult GBM, recognizing that these are different diseases with different molecular profiles. Pediatric GBM accounts for approximately 3 to 15% of all pediatric brain tumors, making it rare but one of the most serious diagnoses a child can receive. The American Brain Tumor Association's overview of pediatric high-grade gliomas is a good introduction to how these tumors are classified today.

Under the current WHO 2021 framework, pediatric high-grade gliomas fall into four main subtypes:

• Diffuse midline glioma, H3 K27-altered - includes tumors in the brainstem, thalamus, and spinal cord; brainstem tumors in this group were formerly called DIPG
• Diffuse hemispheric glioma, H3 G34-mutant - found in the brain hemispheres, more common in older teenagers
• Pediatric-type diffuse high-grade glioma, H3-wildtype and IDH-wildtype - a biologically heterogeneous group
• Infant-type hemispheric glioma - occurring in children under three, often driven by different molecular alterations such as NTRK fusions

These subtypes are defined by molecular alterations, not by location or appearance under a microscope. Which subtype your child has is the foundation of every treatment decision that follows.

How Does Pediatric GBM Compare to Adult GBM?

Sources: NCBI Bookshelf - Pediatric Glioblastoma; Pediatric versus adult high-grade glioma: immunotherapeutic and genomic considerations, PMC 2022.

The biggest difference in the table is the temozolomide row. Temozolomide is the backbone of adult GBM chemotherapy and has a clear evidence base in adults. In children, that evidence is much weaker. A plan adapted from adult GBM management may not match what the child's molecular subtype actually responds to and may miss more targeted options that fit better.

How Does Prognosis Differ by Age in High-Grade Glioma?

Survival figures in pediatric GBM vary considerably by tumor location and molecular subtype. A single number cannot capture this range, and any figure quoted without specifying the subtype should be treated with caution.

For children with hemispheric (non-brainstem) pediatric glioblastoma, reported median survival ranges from roughly 13 to 73 months, with the five-year survival rate estimated at under 20%. Children with hemispheric GBM appear to survive somewhat longer than adults with similar tumors, partly because pediatric hemispheric tumors are more often surgically resectable, and partly because their molecular biology differs in ways not yet fully understood.

For children with diffuse midline glioma (DMG), H3 K27-altered (including brainstem tumors formerly known as DIPG), the situation is considerably harder. Median overall survival for H3 K27-altered DMG has been reported at under 12 to 15 months, with nearly all patients dying within two years of diagnosis. The brainstem location makes surgery unsafe in most cases, and the H3 K27M mutation is associated with resistance to many standard therapies.

Prognosis in this disease is inseparable from molecular profile. If your child's care team is framing prognosis in terms of a broad category like high-grade glioma rather than the specific WHO 2021 molecular subtype, that is something to address. For a clear explanation of how population-level survival figures are built and what they cannot tell you about an individual patient, the article What Median Survival Really Means in Glioblastoma explains the limits of these numbers in plain terms.

How Treatment Differs for Children with GBM

In adult GBM, the Stupp protocol (maximal safe surgical resection followed by concurrent radiation and temozolomide chemotherapy, then adjuvant temozolomide) has been the established standard of care for nearly two decades. In children, no equivalent consensus protocol exists. Treatment is assembled around the individual child's molecular subtype, age, tumor location, and surgical outcome.

Surgery is the first step when it is technically safe. Removing as much tumor as possible while protecting neurological function matters in children as it does in adults, and the evidence that extent of resection affects survival applies to pediatric HGG as well. Many midline and brainstem tumors, however, cannot be safely resected. The article How Glioblastoma Tumor Location Shapes Surgery Options explains how tumor location shapes what surgery can accomplish.

Radiation is used after surgery in most children over three years old, typically following an approach similar to adult GBM. For children under five, radiation planning is often modified or delayed. The developing brain is more vulnerable to radiation than an adult brain, and long-term cognitive and endocrine effects are major concerns in very young patients. Radiation fractionation schedules, total dose, and target volumes may all be adapted specifically for age.

Chemotherapy is where the biggest divergence from adult management occurs. Clinical research has not established temozolomide as a standard treatment for children with high-grade glioma with the same level of evidence as in adults. Some centers still use it alongside radiation (particularly when MGMT methylation is detected), but the evidence is weaker in children, and not all pediatric oncology teams support this use. If temozolomide is proposed for your child, ask the team specifically what evidence supports this choice for the molecular subtype identified, and whether any trial options are more appropriate.

Tumor Treating Fields (TTFields), the device-based therapy that has shown survival benefit in adult GBM, is not a standard treatment for children and has very limited pediatric data. Do not assume it will work the same way in children without specific evidence.

Why Molecular Testing Is the Foundation of Every Decision

Comprehensive molecular testing of the tumor tissue is not optional in pediatric GBM; it shows which WHO 2021 subtype your child has, and that subtype shapes every treatment and trial decision that follows. Ask the care team specifically whether the following have been tested:

• H3 K27M and H3 G34R mutations - identifies the two most common pediatric HGG molecular subgroups
• BRAF V600E mutation - potentially actionable with targeted therapies in BRAF-mutant pediatric gliomas
• NTRK gene fusions - may be targetable with approved TRK inhibitors, more common in infant-type tumors
• FGFR1 and FGFR2 alterations - another potentially targetable driver in some pediatric gliomas
• IDH1 and IDH2 mutation status - almost always wildtype in pediatric GBM but important to confirm
• MGMT promoter methylation - may influence chemotherapy planning even in children
• Comprehensive next-generation sequencing (NGS) panel - captures the full molecular picture and can reveal trial-eligible alterations that smaller panels would miss

Research has found that molecular subtype is the strongest predictor of outcome in pediatric high-grade gliomas and the most rational basis for treatment planning. A child with a BRAF V600E mutation, for example, may be a candidate for a targeted therapy combination that has no role in H3 K27M-mutant disease. Missing actionable alterations at diagnosis (because the panel was too narrow or was not done) can delay access to the right treatment by weeks or months in a disease where time matters.

Clinical Trials: An Early Priority, Not a Last Resort

Because standard chemotherapy has not consistently improved outcomes in pediatric GBM, clinical trials should be considered early, not just after standard treatment fails. For many molecular subtypes, the most evidence-supported approach for a child with high-grade glioma is enrollment in a trial where the treatment is matched to the tumor's specific molecular profile.

Active areas of trial investigation in pediatric high-grade glioma currently include:

• H3 K27M peptide vaccines - immunotherapy designed to train the immune system to target the H3 K27M mutation directly
• ONC201 and related compounds targeting dopamine receptors - may be effective in H3 K27M-mutant tumors
• CAR-T cell therapy directed at GD2, B7-H3, and other surface proteins expressed on pediatric brain tumor cells
• Oncolytic virus therapies delivered by direct injection into the tumor or brainstem
• BRAF and MEK inhibitor combinations for BRAF V600E-mutant pediatric gliomas

The most effective way to search for trials specific to your child's subtype is clinicaltrials.gov using the molecular subtype name (for example, "diffuse midline glioma H3 K27" or "pediatric high-grade glioma BRAF") rather than just "pediatric glioblastoma." The National Brain Tumor Society also maintains a filtered trial finder for pediatric patients. For a structured approach to identifying trials your child may qualify for, the article Clinical Trial Search Strategy for Glioblastoma walks through the qualification logic step by step; much of it applies equally to pediatric trial eligibility.

How Caregivers Can Access a Precision Second Opinion

Getting a second opinion for a child with a high-grade brain tumor is good medical practice. The diagnosis is complex, the WHO classification changed in 2021, and treatment decisions depend on identifying the subtype correctly from the start.

A meaningful second opinion for pediatric glioblastoma should cover:

• Whether the tumor has been correctly classified under the WHO 2021 CNS criteria, not an older framework
• Whether the molecular panel was comprehensive enough to identify all actionable alterations
• Whether BRAF, NTRK, FGFR, and other targetable mutations were specifically looked for
• Whether the proposed treatment plan is consistent with current evidence for this specific molecular subtype
• Whether the child meets eligibility criteria for any currently open clinical trials

Families in countries without specialist pediatric neuro-oncology centers, such as those in the GCC region, sub-Saharan Africa, and parts of South and Southeast Asia, often need to seek expert review outside their local area. Remote expert review of pathology reports, molecular findings, and MRI images is possible without requiring immediate travel. If you are coordinating this process, you can arrange a remote second opinion through Art of Healing Cancer, where the clinical team can review case materials and provide a structured expert assessment of the diagnosis and proposed treatment plan.

When gathering materials for any second opinion, the most important documents to prepare are: the full surgical pathology report including all molecular test results, MRI scans in DICOM format (the raw files, not printed images or screenshots), the operative report from surgery, and any additional genetic panel results. Confirm with the pathology department whether a formalin-fixed paraffin-embedded (FFPE) tissue block from the surgical specimen is still available; specialist centers may need this for additional molecular testing that was not done at the original institution.

If you are at an early stage of pulling these materials together, you can upload reports and imaging through the Glioblastoma Center patient portal to start the process of remote expert review.

When to Talk to Your Doctor

Talk to your child's oncologist or neuro-oncology team before making any changes to the current treatment plan. Ask these questions: Has the tumor been classified under the 2021 WHO CNS criteria with full molecular testing? Was a comprehensive NGS panel performed that covers pediatric-specific drivers (H3 K27M, H3 G34R, BRAF V600E, NTRK fusions, and FGFR alterations) and not just adult GBM markers? What evidence supports the chemotherapy regimen being proposed for this specific molecular subtype? Are there currently open clinical trials for which your child qualifies? If these questions cannot be answered clearly, get a second opinion at a center with pediatric neuro-oncology expertise. This is a reasonable step for such a complex diagnosis.

This article is for general information and is not a substitute for medical advice. Always consult your oncologist or care team about your specific situation.